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OPEN
ORIGINAL ARTICLE
Shifting brain inhibitory balance and connectivity of the
prefrontal cortex of adults with autism spectrum disorder
LA Ajram1,6, J Horder1,6, MA Mendez1,2, A Galanopoulos1,2, LP Brennan1,2, RH Wichers1,2, DM Robertson2, CM Murphy1,2, J Zinkstok2,
G Ivin3, M Heasman3, D Meek2, MD Tricklebank4, GJ Barker4, DJ Lythgoe4, RAE Edden5, SC Williams4,7, DGM Murphy1,2,7 and
GM McAlonan1,2,7
Currently, there are no effective pharmacologic treatments for the core symptoms of autism spectrum disorder (ASD). There is,
nevertheless, potential for progress. For example, recent evidence suggests that the excitatory (E) glutamate and inhibitory (I) GABA
systems may be altered in ASD. However, no prior studies of ASD have examined the ‘responsivity’ of the E–I system to
pharmacologic challenge; or whether E–I modulation alters abnormalities in functional connectivity of brain regions implicated in
the disorder. Therefore, we used magnetic resonance spectroscopy ([1H]MRS) to measure prefrontal E–I ﬂux in response to the
glutamate and GABA acting drug riluzole in adult men with and without ASD. We compared the change in prefrontal ‘Inhibitory
Index’—the GABA fraction within the pool of glutamate plus GABA metabolites—post riluzole challenge; and the impact of riluzole
on differences in resting-state functional connectivity. Despite no baseline differences in E–I balance, there was a signiﬁcant group
difference in response to pharmacologic challenge. Riluzole increased the prefrontal cortex inhibitory index in ASD but decreased it
in controls. There was also a signiﬁcant group difference in prefrontal functional connectivity at baseline, which was abolished by
riluzole within the ASD group. Our results also show, for we believe the ﬁrst time in ASD, that E–I ﬂux can be ‘shifted’ with a
pharmacologic challenge, but that responsivity is signiﬁcantly different from controls. Further, our initial evidence suggests that
abnormalities in functional connectivity can be ‘normalised’ by targeting E–I, even in adults.
Translational Psychiatry (2017) 7, e1137; doi:10.1038/tp.2017.104; published online 23 May 2017
INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental condi-
tion, which impacts on three ‘core’ domains of function–social
interaction, social communication and repetitive behaviours or
interests. ASD has its origins in very early (prenatal) development,
and persists through to adulthood.1 It is clinically diverse; the core
difﬁculties can range in severity from mild to severe, and they are
often accompanied by secondary conditions, such as anxiety and
depression, especially in adulthood.2 This phenotypic variability
likely reﬂects the marked aetiological heterogeneity of the
disorder, and has made the identiﬁcation of a common underlying
pathology challenging. As a result, there are currently no effective
pharmacological treatments for the core symptoms.
There is hope however, as genetic, post-mortem and preclinical
laboratory studies indicate that the differences in the balance
between the brain’s excitatory (E) glutamate and inhibitory (I)
GABA systems may be one of the ﬁnal ‘common pathways’ in
ASD.3 This is perhaps especially true for GABA. For example,
genetic studies have consistently implicated genes regulating
GABAA receptor expression with ASD,
4,5 whereas environmental
risk factors for ASD, such as exposure to maternal inﬂammation in
prenatal life, have been shown to disrupt gene expression across
GABA pathways.6–8
Direct in vivo measurement of glutamate and, more recently,
GABA, is now possible in humans using proton magnetic
resonance spectroscopy ([1H]MRS). However, studies of glutamate
and GABA at baseline in ASD are at variance.9–14 For example,
some have reported an excess of glutamate in the cortex9 and
plasma,15 and in the amygdala and hippocampal regions.10
Conversely, we have reported lower levels of glutamate in the
subcortex.12 GABA has been reported to be lower in the frontal
cortex of children with ASD,11 yet higher in plasma.16 Still others
have observed no differences in brain glutamate and GABA in
ASD.13,17
This divergence of ﬁndings may at least partly reﬂect between-
study differences in (for example) the brain regions examined, age
of participants, medication history and the presence of common
comorbid mental health symptoms such as anxiety (mediated by
GABA18). However, all prior studies examined E–I without
challenging the system, and it is also possible that differences in
glutamate and GABA ‘ﬂux’ contribute to the variety of ﬁndings
reported. This is because glutamate is a precursor of GABA, and
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there is continuous ‘ﬂux’ between glutamate and glutamine, and
glutamate and GABA in the brain.19–23 Glutamic acid decarbox-
ylase (GAD) is a rate limiting enzyme in the glutamate/GABA-
glutamate cycle, and has been reported to be abnormal in
ASD.24,25 Thus, E–I ‘dynamics’ (as opposed to the static state) may
be critical in ASD—but this has never been directly studied in vivo.
Regional E–I dynamics may have widespread inﬂuence by
regulating the functional connectivity of resting-state brain
networks. For example, in typical individuals, prefrontal glutamate
concentration has been shown to correlate with the strength of
prefrontal functional connectivity;26 whereas local GABA concen-
tration predicts the extent of inhibition within the motor
network.27 However, although altered functional connectivity
measures are commonly reported in ASD (for example, see
refs 28–30), no-one has examined if these can be modulated
through E–I.
Therefore, we conducted the present study to compare E–I and
functional connectivity responsivity of the prefrontal cortex in
adult men with and without ASD. We selected the prefrontal
cortex as a region of interest (ROI), because this region is reliably
implicated in the core symptoms in ASD, including deﬁcits in
theory of mind31,32 and the regulation of socio-emotional
responses.33 We used [1H]MRS and resting-state functional
magnetic resonance imaging (fMRI) to measure (respectively)
change in the E–I ﬂux and functional connectivity of the prefrontal
lobe following a pharmacological challenge with the drug riluzole.
Our MRS measure of E–I ﬂux was the fraction of GABA within the
total measured pool of GABA plus glutamate and glutamine (Glx),
which we deﬁned as the ‘Inhibitory Index’. Our measure of
functional connectivity was the strength of correlation (parameter
estimate; PE) between activity in the prefrontal cortex and the rest
of the brain.
We selected the drug riluzole because it has a broad range of
actions at both GABA and glutamate targets,34,35 and it should
therefore modulate glutamate–GABA ﬂux in a majority of
individuals. For example, riluzole blocks the pre-synaptic release
of glutamate, facilitates GABAA receptor activity
36,37 and has been
reported to shift glutamate–glutamine ﬂux in bipolar disorder.38
Importantly, however, the pharmacokinetic and safety proﬁle of
riluzole is well-established; and a single oral dose of 50 mg riluzole,
as used here, reaches a peak plasma concentration 1 h after oral
administration39 and has a very low risk of adverse effects.
MATERIALS AND METHODS
Participants
A priori calculations indicated that a sample size of n=12 is sufﬁcient to
capture a 10% change in MRS measured metabolite concentration at 80%
power, α= 0.05;40 and this is in line with the minimum number needed for
typical fMRI activations.41 However, to increase conﬁdence in our results, a
total of 37 adult males participated in the study; 17 individuals with ASD
and 20 unaffected controls (Table 1). Each individual had two scans and so
each acted as their own ‘control’; this reduced the inter-subject variability
to improve power.
Individuals with ASD were recruited through the National Autism and
ADHD Service for Adults at the Maudsley Hospital, London; a specialist
diagnostic service for adults. All ASD individuals had a consensus clinical
diagnosis of ASD led by a consultant psychiatrist using ICD10 research
criteria;42 and reached Autism Diagnostic Observation Schedule (ADOS)43
algorithm cut-offs in both communication and social domains.
Inclusion criteria were: IQ score above 70; absence of current
psychoactive medication; and being medication free for a minimum of
6 weeks, to avoid possible confounds from drug interactions. Exclusion
criteria were: a comorbid psychiatric or medical disorder that might affect
brain development, for example, epilepsy or psychosis, head injury, or any
genetic or chromosomal disorder associated with ASD, for example,
tuberous sclerosis or fragile X syndrome. The ASD group scored signiﬁcantly
higher (as expected) in their self-rated autism symptom scores (autism
quotient; Po0.001), and anxiety (STAI; Po0.005), but the groups did not
differ in age or IQ (P=0.44 and 0.15, respectively), see Table 1.
All participants provided written informed consent. Ethical approval for
this study was provided by Camden and Islington London NHS Research
Ethics Committee, study reference: 13/LO/0091.
Procedure
Each participant was scanned on two occasions, one week apart. MRI
scanning began 1 h after oral administration of a capsule containing either
50 mg riluzole, or an equivalent placebo. The order of administration was
randomised and double-blind, so that neither the researcher nor
participant knew which capsule was given. We further controlled for
order effects by ensuring that approximately half the individuals in each
group had placebo ﬁrst and the other half had riluzole ﬁrst.
[1H]MRS data acquisition
[1H]MRS data were acquired on a 3 Tesla (3T) GE Excite II Magnetic
Resonance Imaging scanner (GE Medical Systems, Milwaukee, WI, USA).
The scanning protocol included an initial structural MRI scan, namely a 3D
inversion recovery prepared fast spoiled gradient-recalled echo (IR-FSPGR)
acquisition (number of slices = 124, slice thickness = 1.1 mm, inversion time
(TI) = 450 ms, repetition time (TR) = 7.084 ms, echo time (TE) = 2.84 ms, ﬁeld
of view= 280 mm, ﬂip angle = 20°). This was then used to set the voxel
location for the spectroscopy scans.
Single voxel J-edited MEGAPRESS [1H]MRS spectra were then acquired
in a prefrontal cortex region of interest using previously described
methods.12 More speciﬁcally, we obtained spectra from the bilateral
dorsomedial prefrontal cortex (25×30×40 mm3; TR=2000 ms, TE=68 ms),
which included the anterior cingulate cortex. See Figure 1a for an
illustration of the voxel placement.
[1H]MRS data analysis
[1H]MRS spectra were pre-processed using GE SAGE software (SAGE 2007,
General Electric Healthcare Technologies, Milwaukee, WI, USA) to perform
an edit ON–edit OFF subtraction, to extract the unedited spectrum
(equivalent to conventional PRESS spectrum) and also to extract the
unsuppressed water spectrum. These spectra were then quantiﬁed using
jMRUI version 4 software.44 Each [1H]MRS spectrum was manually checked
for quality to ensure adequate signal-to-noise ratio and absence of
artefacts (Figure 1b). If required, artefacts were removed using jMRUI peak
ﬁtting and removal algorithm, if this was sufﬁcient to restore data integrity.
Table 1. Participant demographic and clinical symptoms
ASD Control T (df) P-value
Number 17 20 N/A
Age (years) 33 (2.5) 30 (1.9) − 0.79 (35) 0.44
FSIQ 114 (3.0) 120 (3.5) 1.48 (31) 0.15
AQ 32 (2.2) 13 (1.1) − 0.76 (24) 0
STAI, State 35 (3.3) 24 (0.8) − 3.3 (18) 0.004

















Abbreviations: ADI-R, Autism Diagnostic Interview—revised (Domain A,
social interaction; Domain B, communication; Domain C, restrictive and
repetitive patterns of behaviour); ADOS, Autism Diagnostic Observation
Schedule; AQ, autism quotient; ASD, autism spectrum disorder; FSIQ, Full
Scale Intelligence Quotient; N/A, not applicable; OCI, Obsessive Compul-
sive Inventory; STAI State, State/Trait Anxiety Inventory. Groups differed in
their neuropsychological tests of symptoms linked to ASD, but not in age
or IQ score (Students t-test).
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Metabolite concentrations were estimated using the AMARES algorithm. In
the subtraction spectrum; GABA (including macromolecule45) at 3 p.p.m.,
Glx (Glutamate+Glutamine; as the measure of glutamate) as two peaks at
3.8 and 3.75 p.p.m. and N-acetylaspartate (NAA) at 2.01 p.p.m. were
estimated. In the unedited spectrum; choline at 3.19 p.p.m., creatine at
2.99 p.p.m. and NAA at 2.01 p.p.m. were estimated. Absolute metabolite
concentrations (in institutional units) were then calculated by dividing the
amplitude of each peak by the amplitude of the unsuppressed water peak
from the water spectrum at 0.00 p.p.m.
To quantify E–I ﬂux, an ‘Inhibitory Index’ was deﬁned as the fraction of
GABA relative to total GABA plus Glx, within each voxel, for each subject:
that is, Inhibitory Index=GABA/(GABA+Glx). This inhibitory index does not
represent an absolute ratio of GABA to glutamate molecules in the brain
tissue, as [1H]MRS has different sensitivities for these two molecules. Rather,
the inhibitory index is a relative measurement that theoretically ranges from
0 to 1. Therefore, a value approaching zero would indicate relatively more
Glx (excitation); values close to 1 would indicate more GABA (inhibition).
[1H]MRS voxel composition calculation
Group differences in proportion of white matter, grey matter and
cerebrospinal ﬂuid contained in the voxel (partial volume effects) are a
potential confound for spectroscopy, and a particular consideration for the
present study, as previous literature has found volumetric group
differences between control and ASD subjects.46 The structural MRI was
ﬁrst segmented into grey matter, white matter and cerebrospinal ﬂuid
(CSF) using SPM2.47 The position of the [1H]MRS voxel was then registered
to the corresponding segmented structural scan and the grey matter,
white matter and CSF content of this region was calculated using in-house
software. We found no group differences in the percentage composition of
grey or white matter in the ROI, nor did this change in the presence of
riluzole (Supplementary Table 1). There was however, a signiﬁcant
difference in the percentage CSF composition in ASD. In light of this, we
corrected each metabolite for individual CSF levels prior to analysis and
controlled for both water and CSF levels, as previously described.12
Resting state fMRI BOLD data acquisition
Immediately after [1H]MRS acquisition, in the same scanning session, resting
state functional MRI data were acquired. Resting state fMRI acquisition
parameters were as follows: an echo-planar imaging (EPI) sequence, TR=2 s,
TE =30 ms, 256 volumes. Slice thickness = 3 mm, number of slices = 38, slice
spacing=0.3 mm. Each slice comprised of 64×64 voxels with a ﬁeld of view
of 240 mm, for a ﬁnal voxel size of 3.75 mm×3.75 mm×3.3 mm. Pulse and
respiration parameters were also acquired during the fMRI scan, for the
purposes of correcting for physiological artefacts in the fMRI dataset, using a
photoplethysmogram pulse oximeter and a chest band, respectively.
Resting state fMRI BOLD data analysis
fMRI data were processed using FSL 5.0.0. The following pre-processing
steps were applied: motion correction using MCFLIRT; slice-timing
correction using Fourier-space time-series phase-shifting; non-brain
removal using Brain Extraction Tool (BET); spatial smoothing using a
Gaussian kernel of full width at half maximum (FWHM) 5 mm; grand-mean
intensity normalisation of the entire 4D dataset by a single multiplicative
factor; and highpass temporal ﬁltering (Gaussian-weighted least-squares
straight line ﬁtting, with sigma=50.0 s).
Manual inspection and removal of artefactual components was then
carried out using hypothesis-free probabilistic independent component
Figure 1. [1H]MRS voxel positions and example spectra. (a) Cortical region of interest; medial prefrontal cortex (mPFC) (25 × 30× 40 mm3)
outlined in white, comprising primarily of anterior cingulate cortex. (b) Example spectroscopy output from the prefrontal voxel (Glx
(glutamate+glutamine); GABA; N-acetylaspartate (NAA) identiﬁed using jMRUI spectroscopy software.
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analysis as implemented in MELODIC (multivariate exploratory linear
decomposition into independent components) Version 3.10, part of FSL.48
The decisions as to whether to exclude each component from a given fMRI
scan were made by a researcher blind to group and to drug status.
Statistical analysis
Statistical analysis of demographic, questionnaire, and [1H]MRS data were
performed using IBM SPSS v.22 software (IBM SPSS Statistics for Macintosh,
Version 22.0. Armonk, NY, USA). Figures were generated using GraphPad
Prism version 7 for Windows (GraphPad Software, La Jolla, CA, USA). Age,
IQ and self-reported questionnaire group comparisons were performed
using independent samples t-tests. The numbers included in each MR
analysis depended upon a stringent quality check of data available for
each participant per analyses at each time point.
[1H]MRS. The [1H]MRS voxel composition in each group was compared
using repeated measures two-way ANOVAs with ‘group’ as between-
subjects factor and ‘drug’ as within-subjects factor (control n= 20, ASD
n= 17). The inhibitory index could be calculated at two time points from 27
participants (that is, 54 data-points) and was therefore compared using
repeated measures two-way analysis of variance with ‘group’ as between-
subjects factor and ‘drug’ as within-subjects factor. Where there was a
signiﬁcant group×drug interaction, we also tested for a group difference
in the change in inhibitory index elicited by drug. The State score measure
of anxiety was included as a covariate in these analyses, as anxiety is
closely linked to GABA,49 and participants with ASD scored signiﬁcantly
higher than controls on measures of anxiety (Table 1).
Post-hoc the change in inhibitory index was converted to a z-score
contribution so that the contribution of a change in glutamate to any
change in the inhibitory index following riluzole could be explored using
Pearson’s correlation analyses; and a Fisher ‘r to z’ transformation was used
to compare correlation co-efﬁcients between groups. For consistency
across analyses, the State score measure of anxiety was included as a
covariate. Finally, we screened for any unpredicted effects of group or drug
on other metabolites measured (choline, creatine or N-acetylaspartate);
any difference identiﬁed would have been subject to a threshold of
Po0.01 to accommodate multiple comparisons.
Resting state fMRI connectivity. The anterior cingulate region contained
within the dorsomedial prefrontal cortex voxel was used as the seed in a
whole brain seed-voxel resting state fMRI connectivity analysis of n=18
controls and n=17 ASD subjects. The seed-voxel analysis was performed
using a general linear model implemented in FEAT (FMRI expert analysis
tool) version 5.98 (ref. 48) as follows: for each participant, the mean signal
time course from an anterior cingulate seed region (contained within the
prefrontal cortex MRS voxel; see Figure 2b was ﬁrst extracted using the
fslmeants tool. This time course was entered as an explanatory variable (EV)
in FEAT, and the participant’s pulse, respiration, and the mean signal from
grey, white, and CSF masks were entered as the ﬁve additional EVs of no
interest. We then carried out higher-level fMRI analysis using FLAME (FMRIB’s
local analysis of mixed effects) stage 1. Higher-level EVs included drug
(riluzole or placebo) and group (ASD or control). The Z (Gaussianised T/F)
statistic images were thresholded using clusters determined by Z42.3 and a
cluster-corrected signiﬁcance threshold of P=0.05.50
PE values from the ﬁrst level fMRI data, for each participant, were our
measure of the mean connectivity between the seed and the network of
voxels found at the group level (Figure 2a). High absolute PE values
indicate high connectivity. Full details of the fMRI result can be found in
Supplementary Table 2.
Potentially confounding differences in head movement were examined
by estimating mean absolute displacement and mean relative volume-to-
volume motion using FSL MCFLIRT. There were no group or drug effects on
either parameter (all P40.8).
Figure 2. Functional connectivity differences between controls and ASD. (a) BASELINE: In the control group there was greater connectivity (an
inverse correlation) between a prefrontal seed region and posterior regions compared to ASD (red). (b) The seed region (mPFC) is shown in
black. (Also indicated is a restricted region of connectivity between mPFC and the brain stem/cerebellum (blue) in ASD at baseline). (c)
RILUZOLE: Riluzole increased connectivity (an inverse correlation) between the prefrontal seed and posterior cortices in ASD only. Blue:
riluzoleoplacebo (Po0.05, cluster-corrected). Light blue: voxels in which the within-subjects effect of riluzole vs. placebo is negative in ASD
(Po0.05, cluster-corrected). (d) Change in functional connectivity elicited by Riluzole is signiﬁcantly different between groups (t(26)= 0.394,
Po0.005). (e) Riluzole did not alter the functional connectivity of the prefrontal lobe in controls but ‘restored’ functional connectivity in the
ASD group to control levels post riluzole (connectivity × group Interaction, two-way repeated measures ANOVA; F(1, 26)= 9.696, Po0.005).
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All data are expressed as mean± s.e.m. unless otherwise speciﬁed. A
signiﬁcance threshold of Po0.05 was adopted for all pre-planned
analyses.
RESULTS
Men with ASD have signiﬁcant differences in E–I responsivity
At baseline (that is, placebo), there were no group differences in
the inhibitory index, or absolute levels of GABA or glutamate in
the medial prefrontal cortex region. However, riluzole administra-
tion shifted the inhibitory index in opposite directions in the ASD
and control groups. Speciﬁcally, riluzole increased the proportion
of GABA in the prefrontal cortex of the ASD group but decreased
the proportion of GABA in controls (group× drug interaction;
F(1, 24) = 4.288, Po0.05). This was conﬁrmed by a signiﬁcant group
difference in the change in inhibitory index elicited by riluzole
(F(1, 27) = 4.29, Po0.05). There were no signiﬁcant effects of group
or drug on other metabolites measured (choline, creatine or
N-acetylaspartate). Please see Figure 3.
E–I balance is regulated differently in men with and without ASD
In controls a decrease in inhibitory index (or GABA fraction)
elicited by riluzole was accompanied by an increase in Glx
(r=− 0.705, Po0.01), see Figure 4. In ASD, the increase in the
inhibitory index (or GABA fraction) was not linked to Glx. This
relationship between the change in inhibitory index and change
in glutamate measure in each group was signiﬁcantly different
(Fisher r to z transformation, z= 2.23, Po0.01).
Baseline functional connectivity differences in ASD are
‘normalised’ post riluzole
There was a signiﬁcant group difference in the change in
functional connectivity elicited by riluzole (t(26) = 0.394,
Po0.005). Speciﬁcally, riluzole increased the minimal/absent
baseline prefrontal functional connectivity in the ASD group
towards the control levels; and there was no longer a group
difference in functional connectivity post riluzole (Figure 2).
DISCUSSION
To the best of our knowledge, this study provides the ﬁrst direct
evidence that responsivity of the E–I system and functional
networks in ASD is regulated differently from controls. Speciﬁcally,
in men with ASD the E–I acting drug riluzole increased a prefrontal
cortex inhibitory index but decreased it in controls. Riluzole also
increased prefrontal functional connectivity from ‘absent’ at
baseline in ASD, to control levels.
We found no baseline differences in the level of cortical
glutamate or GABA in men with ASD relative to controls. This is
consistent with some (unpublished data and refs. 17, 51), but not
all,9 previous studies. However, our results indicate that despite a
comparable baseline, the E–I response to a riluzole challenge was
diametrically opposite in men with ASD and controls. In controls,
the decrease in the inhibitory index (or GABA fraction) was
correlated with an increase in Glx. In ASD, riluzole increased the
inhibitory index (or GABA fraction) without changing Glx. Overall,
this pattern of results indicates that riluzole shifts ﬂux towards
GABA in ASD and towards glutamate–glutamine (Glx) in controls.
This unusual E–I responsivity in ASD may help explain other
paradoxical ﬁndings from studies of the way people with ASD
respond to E–I acting medications. For example, GABAA/benzo-
diazepine receptor agonists typically have an inhibitory effect in
non-ASD populations, but can sometimes cause excitation in
individuals with ASD.52,53 This opposite direction of response in
ASD is important because the initial selection of drug candidates
for clinical trials in ASD is often based on their action in unaffected
individuals. If, however, the nature of the brain response in ASD
fundamentally differs from other populations then similar out-
comes cannot be anticipated, and trials are likely to be
unsuccessful. This exacerbates the challenges of identifying
effective pharmacological treatments for ASD. For example, a
number of clinical trials have been based on the presumption that
drugs which increase inhibition in other populations should also
be effective in ASD. These have included the anti-epileptic
medication lamotrigine, which reduces glutamate release in the
cortex, and D-cycloserine, a partial agonist at the NMDA glutamate
receptor. However, neither approach has been successful in
ASD.54–56
The cause of such E–I responsivity differences in ASD is
unknown. However, they may have their origins in early
developmental abnormalities, and perhaps especially in the GABA
inhibitory system. For example, in ASD, it has been proposed that
there is a delay or alteration in the typical ‘switch’ from an
excitatory action of GABA in prenatal life, to its inhibitory action in
the postnatal period.57–60 There is also evidence from a genetic
model of ASD, the neuroligin knock-in mouse, indicating that
GABAergic, but not glutamatergic, signalling is enhanced in early
postnatal development.18 Abnormalities in GABA pathways in ASD
are also evident in later life, and these include a reduction in the
levels of GAD type 65 and 67 in a number of brain regions,24,25
and GABA receptor abnormalities in ASD, including in the anterior
Figure 3. Riluzole increases inhibition in the prefrontal cortex of the
autism spectrum disorder (ASD) group only. Riluzole increased the
inhibitory index in the ASD group, not controls: *Drug×group
interaction; F(1, 24)= 4.288, Po0.05. Post-hoc analyses demonstrate a
signiﬁcant difference between groups in the change in inhibitory
index after riluzole administration: ANCOVA; F(1, 27)= 4.290, Po0.05.
Results are expressed as mean (± s.e.m.) and are corrected for State
anxiety score.
Figure 4. Inhibitory tone is regulated differently in men with and
without autism spectrum disorder (ASD). The change in inhibitory
index was negatively correlated with changes in Glx in controls
(Pearson correlation; r=−0.705, Po0.01), but not men with ASD
(r= 0.357, P= 0.28). Furthermore, there was a signiﬁcant group
difference in correlation coefﬁcient (Fisher r to z transform, z= 2.23,
Po0.01). Results are expressed as z-scores ((value−mean)/standard
deviation) and are corrected for State anxiety score.
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cingulate component of the prefrontal cortex voxel sampled
here.61,62 Thus, in ASD, early aberrations in E–I pathways may lead
to persistent alterations, not necessarily in the absolute amount of
GABA or glutamate but in their ﬂux, receptor availability and
action, and hence on their subsequent inﬂuence on brain network
activity.
Consistent with this, our work suggests that the typical
functional connectivity of a prefrontal-posterior brain network is
absent in ASD. Similar baseline differences in resting state
networks in ASD have been observed before, and our ﬁndings
are consistent with the ‘long range underconnectivity’ reported in
ASD (reviewed in Geschwind and Levitt63). Moreover, the
dorsomedial prefrontal cortex/anterior cingulate region of interest
examined in our study has been speciﬁcally identiﬁed as the
critical node within a disconnected system which contributes to
the social difﬁculties found in ASD.63,64 This accumulation of
observations of long-range underconnectivity in ASD has lead to
the conceptualization of the condition as a ‘Developmental
Disconnection Syndrome’.63
Developmental disconnection in ASD has been suggested to
arise in two ways: (i) ‘a weakening of already formed connections’;
or (ii) ‘a failure of certain connections to establish correct
organisation de novo’.63 This then has implications for the severity
of the ASD phenotype, with a failure to establish correct
connections theroetically leading to more severe features. Here,
riluzole (re-)established a functional relationship between the
prefrontal and posterior cortices in high functioning adults with
ASD which was similar to controls. This implies that any
developmental disconnection in our cohort of autistic men is
more likely to be ‘a weakening’ rather than an irreversible ‘failure’
of connectivity per se. In other words, the functional architecture
of brain in ASD, though not measureable at baseline, was still in
place and revealed by riluzole.
Clinically, riluzole has shown promise in reducing symptoms in
some65,66 but not all individuals with ASD.67 Thus, as expected in a
spectrum condition like ASD, not everyone responds to the same
extent to a drug challenge. In future studies, a neuroimaging
approach such as the one used here could begin to help
personalise medicine for ASD. For instance, future studies
investigating clinical treatment with riluzole may be of interest
in cohorts enriched with individuals who can be shown to mount
a brain response to a single test dose.
The limitations of our study include the inherently limited
spatial resolution of [1H]MRS, which restricts measurements to
‘bulk’ levels of metabolites. This macroscopic approach provides
insight to the gross regional changes in E–I ﬂux after challenge
(see for example, Brennan et al.38), but does not allow for circuit
level analysis. Future work is warranted to dissect the circuitry of
the prefrontal cortex in more detail. One way of doing this may be
to use more directed pharmacological probes, for example,
speciﬁc to different GABA receptor sub-types.
We also acknowledge that, although based upon prior power
calculations, the sample size for this study was still modest. This
precluded further exploration of the relationship between
symptom proﬁle and E–I responsivity in ASD. Future work will
be required to conﬁrm the ﬁndings from this ‘Proof of Concept’
work, and determine if these are generalisable, for example, to
females with ASD, to other age groups and/or to individuals with
intellectual difﬁculties.
In conclusion, using [1H]MRS and fMRI, we found that E–I ﬂux
and functional connectivity of the prefrontal cortex are differen-
tially regulated in adults with ASD compared with the controls.
Importantly, inhibitory tone and functional connectivity can be
shifted pharmacologically—and even in adults with ASD.
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